Company
Headquarters: Friendswood, TX, United States
Employees: 342
CEO: Mr. Derek J. Maetzold
$1.12 Billion
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $222.61 B |
| Danaher | $164.98 B |
| Siemens Healthineers AG | $57.84 B |
| IDEXX Laboratories, Inc. | $53.62 B |
| Lonza Group Ltd | $47.58 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $250.7 M |
| EBITDA | $-29,148,000 |
| Gross Profit TTM | $174.8 M |
| Profit Margin | -12.28% |
| Operating Margin | -7.50% |
| Quarterly Revenue Growth | 73.60% |
Castle Biosciences, Inc. has the following listings and related stock indices.
Stock: NASDAQ: CSTL